SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vion (formerly Oncorx) interesting play on Gene Therapy
An SI Board Since April 1996
Posts SubjectMarks Bans Symbol
370 14 0 VION
Emcee:  Type:  Unmoderated
Introduction Market Data Compact
Vion (OCRX) is a R&D biotech company with several near and intermediate term product developments. For example, it has licensed from Yale University, exclusive rights to patent applications on several antiviral agents having activity against Hepatits B Virus (HBV), HIV, FddC and others. Vion has also licensed a family of highly potent Ribonucleotide Reductase Inhibitors which appear to act against solid tumors. Clinical trials may start in early 1997.

But what interests me (and my PhD buddies) the most is their program at Yale called Tumor Amplified Prodrug Enzyme Therapy (TAPET), a form of gene therapy. Microorganism are used for the delivery of prodrug converting enzymes to tumor tissues. These microorganisms have been designed to be highly selective for tumor tissue vs. normal issues. The microorganisms multiply selectively in tumor tissue to levels 1,000-10,000 times greater than found in normal tissue. The converted tumors then begin to express prodrug enzymes which in turn release tumor growth inhibitors causing significant regression in animal tumors. I haven't found anyone following this one!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
370We're back - Vion has risen from ashes. Stock rose 32% today to $3.75 (up .buffalodon2003-8/12/2009
369I thought that I'd give this old board a post in light of Vion's Standarbuffalodon2003-5/3/2009
368I concur. The announcement of a reverse split provicized the non-buying fate. buffalodon2003-1/24/2008
367I can't believe the how badly I miscalculated by not selling in Dec. Cost gonnahappensoon-1/24/2008
366Does anyone know purpose of the 1/17 SEC release?buffalodon2003-1/22/2008
365A poster on yahoo just indicated that Megastockpick shows Vion as their top pickbuffalodon2003-1/21/2008
364Does any interested parties in Vion have any constructive comments regarding thebuffalodon2003-1/9/2008
363Based upon my understanding of past events and interpretation, I believe they inbuffalodon2003-12/11/2007
362They need a partnership to get them up to $3 or higher. My biggest question is Keith Feral-12/11/2007
361I agree with the selloff. Imo, the new purchases at the .56 - .65 pps made a nibuffalodon2003-12/10/2007
360Relax, it's thinly traded. The market makers and momo traders had to sell akdd999-12/10/2007
359That close was not what I expected. Down 3 cents?Keith Feral-12/10/2007
358The company seemed to think they could file an NDA in 2008 with the results fromKeith Feral-12/10/2007
357Good news on Vion. I'll have to go back and listen to the CC from this mornKeith Feral-12/10/2007
356They just posted their results on the website. vionpharm.comKeith Feral-12/8/2007
355This has been and is a good buy position if hedging longer positions. With the buffalodon2003-12/7/2007
354Phase 2 results are going to be released on Saturday.Keith Feral-12/7/2007
353Day is Done....Gone the Sun...gonnahappensoon-11/1/2007
352Where is the insider buying?gonnahappensoon3-10/25/2007
351Volume still has been up lately. Some suggest maybe short covering? I was in gonnahappensoon3-10/12/2007
350I concur that Vion is making a slight consistent move (except for today). I'buffalodon2003-10/12/2007
349Yes, I am watching it also. Maybe! if things would go very right we could see $4okee-boy-10/12/2007
348Anyone watching this climb? Love to see trial resumed and the stock back at 2 gonnahappensoon3-10/11/2007
347I was also encouraged by detail in news release. The midpoint was promising befbuffalodon2003-8/16/2007
346Vion Completes Accrual of 85 Patients to its Pivotal Phase II Trial of CloretaziJim Oravetz-8/15/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News